BG105715A - Комбинирана хемотерапия - Google Patents

Комбинирана хемотерапия

Info

Publication number
BG105715A
BG105715A BG105715A BG10571501A BG105715A BG 105715 A BG105715 A BG 105715A BG 105715 A BG105715 A BG 105715A BG 10571501 A BG10571501 A BG 10571501A BG 105715 A BG105715 A BG 105715A
Authority
BG
Bulgaria
Prior art keywords
combination chemotherapy
combination
paclitaxel
meanings
substituents
Prior art date
Application number
BG105715A
Other languages
English (en)
Inventor
Richard Gowan
- LEOPOLD Judith SEBOLT
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105715A publication Critical patent/BG105715A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до митотични инхибитори като паклитаксел, които имат подобрена противотуморна активност, когато се използват в комбинация съсселективен МЕК инхибитор, по-специално фениламиносъединение с формули, в които заместителите имат значенията, посочени в описанието.
BG105715A 1998-12-22 2001-07-18 Комбинирана хемотерапия BG105715A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
BG105715A true BG105715A (bg) 2002-04-30

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105715A BG105715A (bg) 1998-12-22 2001-07-18 Комбинирана хемотерапия

Country Status (31)

Country Link
EP (1) EP1140291B1 (bg)
JP (1) JP2002532570A (bg)
KR (1) KR20010099877A (bg)
CN (1) CN1333698A (bg)
AP (1) AP2001002175A0 (bg)
AT (1) ATE310567T1 (bg)
AU (1) AU2203900A (bg)
BG (1) BG105715A (bg)
BR (1) BR9916839A (bg)
CA (1) CA2352326A1 (bg)
CZ (1) CZ20012139A3 (bg)
DE (1) DE69928568T2 (bg)
EA (1) EA200100687A1 (bg)
EE (1) EE200100339A (bg)
ES (1) ES2253928T3 (bg)
GE (1) GEP20043172B (bg)
HK (1) HK1042057A1 (bg)
HR (1) HRP20010473A2 (bg)
HU (1) HUP0104844A3 (bg)
ID (1) ID30250A (bg)
IL (1) IL143939A0 (bg)
IS (1) IS5969A (bg)
MA (1) MA26768A1 (bg)
NO (1) NO20013099L (bg)
NZ (1) NZ512859A (bg)
OA (1) OA11733A (bg)
PL (1) PL348326A1 (bg)
SK (1) SK8712001A3 (bg)
TR (1) TR200101871T2 (bg)
WO (1) WO2000037141A1 (bg)
YU (1) YU45401A (bg)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
WO2002017952A2 (en) 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
BRPI0415018A (pt) * 2003-10-08 2006-11-28 Teijin Pharma Ltd métodos para a produção de derivados de aminopirrolidina e de antranilamida, e, composto
BRPI0415710A (pt) 2003-10-21 2006-12-19 Warner Lambert Co formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
DK1802579T3 (da) 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
KR101400905B1 (ko) 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
WO1998042830A2 (en) * 1997-03-21 1998-10-01 Board Of Regents, The University Of Texas System Noey2 gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
AP2001002175A0 (en) 2001-06-21
IS5969A (is) 2001-06-14
HRP20010473A2 (en) 2002-08-31
WO2000037141A1 (en) 2000-06-29
CN1333698A (zh) 2002-01-30
EE200100339A (et) 2002-10-15
NZ512859A (en) 2004-06-25
EP1140291A1 (en) 2001-10-10
DE69928568T2 (de) 2006-07-27
EP1140291B1 (en) 2005-11-23
HK1042057A1 (zh) 2002-08-02
CA2352326A1 (en) 2000-06-29
JP2002532570A (ja) 2002-10-02
EA200100687A1 (ru) 2001-12-24
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
KR20010099877A (ko) 2001-11-09
IL143939A0 (en) 2002-04-21
PL348326A1 (en) 2002-05-20
AU2203900A (en) 2000-07-12
BR9916839A (pt) 2001-10-09
CZ20012139A3 (cs) 2002-01-16
HUP0104844A3 (en) 2003-05-28
OA11733A (en) 2005-05-12
ATE310567T1 (de) 2005-12-15
WO2000037141A9 (en) 2000-12-07
MA26768A1 (fr) 2004-12-20
DE69928568D1 (de) 2005-12-29
SK8712001A3 (en) 2002-02-05
TR200101871T2 (tr) 2001-10-22
ID30250A (id) 2001-11-15
NO20013099L (no) 2001-08-20
ES2253928T3 (es) 2006-06-01
NO20013099D0 (no) 2001-06-21
YU45401A (sh) 2004-07-15

Similar Documents

Publication Publication Date Title
BG105715A (bg) Комбинирана хемотерапия
BG105369A (bg) Арилпиперазини и тяхното използване като инхибитори на металопротеиназа (ммр)
AP2001002103A0 (en) Substituted phenyl derivatives, their preparation and use.
ATE218859T1 (de) Liganden des neuropeptids y
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
CY2509B1 (en) New thiazole derivatives with phosphodiesterase-inhibitting effect
AU3110999A (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
GEP20084500B (en) Heterocyclocarboxamide derivatives
EP1277754A4 (en) Imidazopyridine DERIVATIVES
PL350027A1 (en) C10 heterosubstituted acetate taxanes as antitumor agents
PL343374A1 (en) Anti-inflammatory, antibacterial benzyl phenol agents
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
MX9708827A (es) Derivados novedosos de amidina utiles como inhibidores de agregacion plaquetaria y como vasodilatadores.
AU7259701A (en) Coumarin derivatives with comt inhibiting activity
BG105539A (bg) Елетриптан хидробромид монохидрат
GB2324091A (en) Metalloproteinase inhibitors
BG105964A (bg) Таксани с карбонатен заместител при с(10) и приложението им като антитуморни агенти
MXPA05006957A (es) Nuevos derivados de fosforamida.
WO2000035428A3 (de) Tricyclische stickstoffheterocyclen als pde iv inhibitoren
BG105966A (bg) Таксани с карбонатен заместител на с(7) и приложението им като антитуморни агенти
BG105965A (bg) Таксани с естерен заместител на с(10) и приложението им като антитуморни агенти
MX9602949A (es) 2-oxa y tia-zolinas artropodicidas.
MY119841A (en) Cephalosporines having cyclic aminoguanidine substituents as antibiotics.
RS51143B (sr) Novi benzonaftiridini